Clinical Trial Update: A Study to Determine the Optimal Dose and Frequency of ALDP001 Nasal Spray in Adults With Seasonal Allergic Rhinitis Under Allergen Exposure [Phase 2]

View source ↗

Summary

A Phase 2 trial to determine the optimal dose and dosing frequency of ALDP001 nasal spray for adults with seasonal allergic rhinitis is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Seasonal Allergic Rhinitis

Drugs mentioned

• ALDP001 Nasal Spray (ALDP001)

Snippet

Sponsor: Alixer Nexgen Therapeutics Limited | Conditions: Seasonal Allergic Rhinitis (SAR) | Phase 2 | Status: RECRUITING